Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | DNM2 | P50570 | 4/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7122679 | 1.00 | MAPT (0.35) | MAPTHTTNPSR1DNM2TLR8 | |
| SCHEMBL7124368 | 1.00 | MAPT (0.35) | MAPTHTTNPSR1DNM2TLR8 | |
| SCHEMBL7124421 | 1.00 | MAPT (0.35) | MAPTHTTNPSR1DNM2TLR8 | |
| SCHEMBL7124409 | 1.00 | MAPT (0.35) | MAPTHTTNPSR1DNM2TLR8 | |
| SCHEMBL7123826 | 1.00 | MAPT (0.35) | MAPTHTTNPSR1DNM2TLR8 | |
| SCHEMBL7121632 | 1.00 | MAPT (0.35) | MAPTHTTNPSR1DNM2TLR8 | |
| SCHEMBL7122726 | 1.00 | MAPT (0.35) | MAPTHTTNPSR1DNM2TLR8 | |
| SCHEMBL7124475 | 1.00 | MAPT (0.35) | MAPTHTTNPSR1DNM2TLR8 | |
| SCHEMBL7125685 | 1.00 | MAPT (0.35) | MAPTHTTNPSR1DNM2TLR8 | |
| SCHEMBL7121638 | 1.00 | MAPT (0.35) | MAPTHTTNPSR1DNM2TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653317-B2 | Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss | SOCIETE L'OREAL S.A. (FR) | 2003-11-25 | — | — | US | claimed |
| US-20030130294-A1 | Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss | MAHE YANN (FR) | 2003-07-10 | — | — | US | claimed |
| US-6455054-B2 | THERAPY FOR SKIN DISORDERS | SOCIETE L'OREAL S.A. (FR) | 2002-09-24 | — | — | US | claimed |
| US-20010051139-A1 | TREATING SKIN AFFLICTIONS/CONDITIONS WITH 2-AMINO-4-ALKYLAMINOPYRIMIDINE 3-OXIDE COMPOUNDS | SOCIETE L'OREAL S.A. (FR) | 2001-12-13 | — | — | US | claimed |
| US-20010044444-A1 | Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss | MAHE YANN (FR) | 2001-11-22 | — | — | US | claimed |
| US-6291468-B1 | Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss | SOCIETE L'OREAL S.A. (FR) | 2001-09-18 | — | — | US | claimed |
| US-6653317-B2 | Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss | SOCIETE L'OREAL S.A. (FR) | 2003-11-25 | — | — | US | disclosed |
| US-20030130294-A1 | Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss | MAHE YANN (FR) | 2003-07-10 | — | — | US | disclosed |
| US-6511659-B2 | Treatment of alopecia, cosmetics | SOCIETE L'OREAL S.A. (FR) | 2003-01-28 | — | — | US | disclosed |
| US-6455054-B2 | THERAPY FOR SKIN DISORDERS | SOCIETE L'OREAL S.A. (FR) | 2002-09-24 | — | — | US | disclosed |
| US-20010051139-A1 | TREATING SKIN AFFLICTIONS/CONDITIONS WITH 2-AMINO-4-ALKYLAMINOPYRIMIDINE 3-OXIDE COMPOUNDS | SOCIETE L'OREAL S.A. (FR) | 2001-12-13 | — | — | US | disclosed |
| US-6291468-B1 | Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss | SOCIETE L'OREAL S.A. (FR) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051139-A1 | TREATING SKIN AFFLICTIONS/CONDITIONS WITH 2-AMINO-4-ALKYLAMINOPYRIMIDINE 3-OXIDE COMPOUNDS | TPMT, IL33, PTGS2 | MAPT 97/4885HTT 3540/4885NPSR1 1139/4885 |
| US-20030130294-A1 | Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss | TK2, TYR, MTR | MAPT 4148/4885HTT 3359/4885NPSR1 4040/4885 |
| US-20010044444-A1 | Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss | TK2, TYR, MTR | MAPT 4097/4885HTT 3489/4885NPSR1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.